Findings show accumulation of neuronal injury and functional decline suggesting that changes in gonadal hormones may be associated with changes in functional and biological markers in MS.
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
A promising new treatment accelerates myelin repair, potentially restoring vision and improving brain function in people with ...
A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
GlobalData on MSN4d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesTeva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
Researchers at the University of Colorado Anschutz Medical Campus have identified LL-341070, a promising drug candidate that ...
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback